Federated Hermes, Inc. Nuvation Bio Inc. Transaction History

Federated Hermes, Inc.

$43.6 Billion
Q3 2024

A detailed history of Federated Hermes, Inc. transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 367,942 shares of NUVB stock, worth $1.04 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

367,942

Previous 361,406 1.81%

Holding current value

$1.04 Million

Previous $1.06 Million 19.81%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$2.3 - $3.83 $15,032 - $25,032	6,536 Added 1.81%	367,942 $846,000
Q2 2024 Aug 08, 2024	BUY	$2.58 - $3.69 $1,449 - $2,073	562 Added 0.16%	361,406 $1.06 Million
Q1 2024 May 14, 2024	BUY	$1.46 - $3.97 $1,712 - $4,656	1,173 Added 0.33%	360,844 $1.31 Million
Q4 2023 Jan 31, 2024	SELL	$0.96 - $1.53 $7,337 - $11,693	-7,643 Reduced 2.08%	359,671 $543,000
Q3 2023 Nov 13, 2023	SELL	$1.26 - $2.1 $6,930 - $11,550	-5,500 Reduced 1.48%	367,314 $492,000
Q2 2023 Aug 14, 2023	BUY	$1.56 - $1.84 $581,589 - $685,977	372,814 New	372,814 $671,000
Q3 2022 Nov 14, 2022	BUY	$0.29 - $4.04 $3,828 - $53,340	13,203 Added 261.39%	18,254 $41,000
Q2 2022 Aug 15, 2022	SELL	$3.24 - $5.85 $13,284 - $23,985	-4,100 Reduced 44.8%	5,051 $16,000
Q1 2022 May 13, 2022	BUY	$4.6 - $8.83 $7,162 - $13,748	1,557 Added 20.5%	9,151 $48,000
Q4 2021 Feb 14, 2022	SELL	$7.75 - $10.05 $84,025 - $108,962	-10,842 Reduced 58.81%	7,594 $65,000
Q3 2021 Nov 15, 2021	BUY	$7.78 - $10.0 $143,432 - $184,360	18,436 New	18,436 $183,000

Others Institutions Holding NUVB

# of Institutions

158

Shares Held

157M

Call Options Held

3.2K

Put Options Held

98.7K

View Full List

About Nuvation Bio Inc.

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $613M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

More about NUVB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.

Account

Federated Hermes, Inc. Nuvation Bio Inc. Transaction History